GlaxoSmithKline Consumer Healthcare Limited announces results for the quarter and full year ended March 31, 2018

GlaxoSmithKline Consumer Healthcare Limited announces results for the quarter andfull year ended March 31, 2018

 

  • Comparable* Revenue growth of 8%, PBT growth of 18.3% for the fourth quarter ended March 31, 2018
  • Board of Directors of the Company recommended a Dividend at the rate of Rs. 75 per equity share for the 12 months period ended March 31, 2018

 

 

Gurugram, 11 May, 2018: GlaxoSmithKline Consumer Healthcare Limited today declared its financial results for the fourth quarter and full year ended March 31, 2018. The comparable* Revenue for the company recorded a growth of 8%. The quarter reported revenue of Rs. 1,180 crore, while the PBT is at Rs. 319 crores, which is an increase by 18.3% compared to last quarter. The quarter also witnessed a volume growth at 5.3%. For the full year, the comparable* revenue is Rs. 4,377 crores which is an increase by 7.6% and the PBT is at Rs. 1,074 crores, which is an increase by 6.3% compared to last year.

 

The Board of Directors of the Company recommended a Dividend at the rate of Rs. 75 per equity share of Rs. 10 each for the year ended March 31, 2018.

 

Commenting on the results, Navneet Saluja, Managing Director, GlaxoSmithKline Consumer Healthcare Limited said, “I am very satisfied with the overall quarter performance specially on Volume growth in our health drinks portfolio and the share gain achieved by our lead brand Horlicks. The quarter witnessed the launch of Protein+, an advanced nutrition product, that will significantly strengthen our position in the high-science range and will further reinforce our leadership in the HFD category.”

 

“As a company, we remain committed to driving the nutrition agenda for the country through various initiatives which are also in line with Government’s National Nutrition Mission. We remain committed to our ACCESS & REACH agenda.  Our rural coverage across 9 states where we operate has increased to 21,500 villages through Rural sub distributors and Village Level Entrepreneurs (VLE’s). Now we reach to around 3.5 lakh outlets directly in this channel. With a strong Government focus on Nutrition, better than expected monsoons and an improved business environment, we are bullish about the coming quarters” added Saluja.

 

 Performance Highlights:

  • Base Horlicks gained 1.1% market share to exit Q4’18 at 32.5%
  • Boost continued to maintain its strong growth momentum with double digit volume growth.
  • Horlicks Protein+ was launched with a 360-degree campaign with R. Madhavan and extensive expert marketing support under high science
  • Boost launched a new thematic ‘Play A Bigger Game 3.0’ with a special unveiling by Virat Kohli through his social media page

 

About GlaxoSmithKline Consumer Healthcare Ltd

GSK Consumer Healthcare Ltd is the category leader in Indian health food drinks industry. Our flagship product Horlicks leads the market, while Boost is among the top three health food drink brands that India prefers. Our manufacturing plants are located in Nabha, Rajahmundry and Sonepat. In India we have an engaged workforce of over 3800 employees. GSK also markets and distributes a range of everyday health products such as Eno, Crocin, Iodex and Sensodyne. Our marketing and distribution network comprises over 800 distributors and a direct coverage of over 8 lakh retail outlets.

 

GSK Consumer Healthcare Ltd is an associate of GlaxoSmithKline plc. of U.K, one of world’s largest consumer healthcare companies. We have a heritage that goes back over 160 years. Our purpose is to help more people around the world to do more, feel better and live longer with everyday healthcare products.  Our goal is to build a global, growing business - we call a Fast-Moving Consumer Healthcare (FMCH) company - dedicated to everyday healthcare with all of the scientific expertise and quality guarantees that demands, working at the speed and with the genuine consumer understanding the modern world expects.

 

GSK Consumer Healthcare globally owns some of the world’s best loved healthcare brands, successful in over 100 countries. These include Sensodyne, Theraflu, Paradontax, Panadol, Polident, Otrivin, Horlicks and Physiogel

 

 

Media Contacts

Genesis Burson-Marsteller

Neeraj Dhankher: Neeraj.dhankher@bm.com / +91 9818342319

M Sindhu: m.sindhu@bm.com /+91 9899428304

 

GlaxoSmithKline Consumer Healithcare

Deepa Dey: deepa.d.dey@gsk.com

Kinshuk Gupta: kinshuk.x.gupta@gsk.com